The Prevalence of Positivity of Anti Tissue Transglutaminase in Patients with Short Stature in Pediatric Endocrinology Clinic of Tishreen Hospital in Lattakia

Background: Short stature is a common problem to practicing pediatricians. It results from various etiologies, which are categorized as normal variants and pathological causes. Normal variant short stature consists of Familial Short Stature (FSS) and Constitutional Growth Delay (CGD), while pathological causes are subdivided into endocrine diseases, clinically defined syndromes, chronic diseases, metabolic diseases and others. There are not so much data available in Bangladesh in this respect. So, present study was conducted to know the common causes of short stature.Methods: This cross-sectional study was done in pediatric endocrinology clinic of Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh from January 2017 to August 2018. One hundred children with short stature meeting inclusion criteria were recruited after taking an informed consent. The detailed history, physical examination including anthropometric measurements and relevant investigations were done. Data were recorded on a predesigned questionnaire for final analysis.Results: The common causes of short stature identified were familial short stature (FSS) 51% cases, Constitutional Growth Delay (CGD) 14% cases and hypothyroidism 12% cases. Other less common causes of short stature were Growth Hormone Deficiency (GHD) 8% cases, malnutrition 6% cases and genetic syndrome 5% cases.Conclusions: FSS and CGD were the leading cause of short stature in children. Endocrinological causes were the most common cause of short stature after normal variant while nonendocrine causes were the least.

Download Full-text

Etiologies of short stature in a pediatric endocrine clinic in Southern Thailand

Journal of Pediatric Endocrinology and Metabolism ◽

10.1515/jpem-2017-0205 ◽

2017 ◽

Vol 30 (12) ◽

Cited By ~ 2

Author(s):

Tansit Saengkaew ◽

Edward McNeil ◽

Somchit Jaruratanasirikul

Keyword(s):

Short Stature ◽

Standard Deviation Score ◽

Population Data ◽

Hormone Deficiency ◽

Pediatric Endocrinology ◽

Gender And Age ◽

Southern Thailand ◽

Common Etiology ◽

The Common ◽

Endocrinology Clinic

AbstractBackground:Short stature is one of the common disorders referred for investigation of an endocrine disorder. The etiologies of short stature vary and are commonly grouped into pathological and non-pathological disorders. The objective of the study was to determine the etiologies and describe the characteristics of short stature patients who attended the Pediatric Endocrinology Clinic and to compare factors between normal variant short stature (NVSS) and growth hormone deficiency (GHD).Methods:This was a retrospective review of 572 patients referred for evaluation of short stature between January 2004 and December 2015. Short stature was defined as height below −2 standard deviation score (SDS) by gender and age based on population data of Thai children.Results:In total, 521 patients were identified as having short stature. NVSS was the most common etiology (44.9%) and pathological short stature was found in 35.3% of the cases, of which 21.2% had GHD. The median age at presentation of NVSS patients was 8.6 years while that of pathological short stature patients was 2.1 years (p<0.001). Patients with NVSS had significantly higher median height SDS (HSDS) than patients with pathological diseases. The common etiologies in severe short patients, defined by HSDS ≤−3, were syndromic short stature (16.2%) and GHD (14.1%). In the moderate short stature group (HSDS between −2 and −3), constitutional delay of growth and puberty (CDGP) was the most common etiology (34.1%).Conclusions:NVSS was the most common etiology of short stature, followed by syndromic short stature and GHD. Physical examination is crucial to identify GHD from syndromic short patients.

Download Full-text

Telemedicine experiences at a pediatric endocrinology clinic during the COVID-19 pandemic

Irish Journal of Medical Science (1971 -) ◽

10.1007/s11845-021-02677-1 ◽

2021 ◽

Author(s):

Yasemin Denkboy Ongen ◽

Erdal Eren ◽

Kadriye Cansu Sahin ◽

Meltem Buhur Pirimoglu ◽

Halil Saglam ◽

...

Keyword(s):

Pediatric Endocrinology ◽

Endocrinology Clinic

Download Full-text

Frequency of familial short stature identified in children presenting with short stature at a Tertiary Care Hospital in Multan, Pakistan.

The Professional Medical Journal ◽

10.29309/tpmj/2021.28.07.5328 ◽

2021 ◽

Vol 28 (7) ◽

pp. 993-996

Author(s):

Waqas Imran Khan ◽

◽

Asia Noreen ◽

Summera Tabasum ◽

◽

...

Keyword(s):

Short Stature ◽

Tertiary Care ◽

Female Gender ◽

P Value ◽

Care Hospital ◽

Pediatric Endocrinology ◽

Multicenter Studies ◽

Study Population ◽

Age Range ◽

Study Setting

Objectives: The objective of my study was to determine the frequency of familial short height in children aged 3 to 14 years with short height. Study Design: Descriptive study. Setting: Department of Pediatric Endocrinology at The Children Hospital & Institute of Child health Multan (CH& ICH). Period: 1st November 2018 to 31st October 2019. Material & Methods: Eighty four patients were enrolled after taking informed consent from parents/guardians. Heights of all patients, parental heights, mid parental heights were plotted on CDC growth charts. Patients having familial short stature were noted down. Results: Out of 84 patients, 59 (70.2%) were males and 25 (29.85%) were females. Age range was 3-14 years. Mean age of the population was 8.68 ± 3.42 years and mean height and weight were 114.29 ± 24.62cm and 28.95±10.01 kg, respectively. Mean height for mother and father of the patients were 154.39 ±4.56cm and 171.10 ± 3.52cm, respectively. Out of 84 children, 21 (25%) patients had FSS. In our study population FSS was more seen in children < 8 years of age, female gender and families with income of > 20K/months with p value of 0.879, 0.129 and 0.592 respectively. Conclusion: Majority of children presenting with short stature have FSS and CDG and do not have an endocrine disorder. In our study, frequency of familial short stature in children aged 3 to 14 years was 25%. The results should be validated in multicenter studies.

Download Full-text

Increased frequency of idiopathic central precocious puberty in girls during the COVID-19 pandemic: preliminary results of a tertiary center study

Journal of Pediatric Endocrinology and Metabolism ◽

10.1515/jpem-2021-0565 ◽

2021 ◽

Vol 0 (0) ◽

Author(s):

Sezer Acar ◽

Behzat Özkan

Keyword(s):

Precocious Puberty ◽

Clinical Characteristics ◽

Laboratory Data ◽

Central Precocious Puberty ◽

Pediatric Endocrinology ◽

Idiopathic Central Precocious Puberty ◽

Tertiary Center ◽

One Year ◽

The One ◽

Endocrinology Clinic

Abstract Objectives Recent studies have demonstrated an increase in the frequency of idiopathic central precocious puberty (CPP) during the severe acute respiratory syndrome coronavirus 2 (COVID-19) pandemic. We compared the demographic, anthropometric, and clinical characteristics of idiopathic CPP patients diagnosed during a one-year period of the COVID-19 pandemic with the characteristics of patients diagnosed during the same period in the previous three-years. Methods Demographic, clinical, anthropometric, and laboratory data of all patients diagnosed in our Pediatric Endocrinology clinic with idiopathic CPP during a one-year period of the COVID-19 pandemic (April 2020–March 2021) and a three-year period before the pandemic (April 2017–March 2020) were evaluated retrospectively. Results A total of 124 patients (124 girls, zero boys) diagnosed with idiopathic CPP were included in this study. Sixty-six patients in the three-year period before the COVID-19 pandemic (April 2017–March 2020) and 58 patients (46.8%) in the one-year period during the COVID-19 pandemic period (April 2020–March 2021) were diagnosed with idiopathic CPP. Conclusions This study’s findings suggest that the number of girls diagnosed with idiopathic CPP during the one-year study period during the pandemic was more than double that of any of the previous three-years.

Download Full-text

Influence of the Basal Metabolic Profile on the Evolution of the Pediatric Patient with Obesity

10.5772/intechopen.98526 ◽

2021 ◽

Author(s):

Belén Fernández ◽

Ainhoa Sarasua Miranda ◽

Isabel Lorente Blázquez ◽

Ignacio Diez López

Keyword(s):

Body Composition ◽

Childhood Obesity ◽

Pediatric Population ◽

Tertiary Hospital ◽

The Body ◽

Basal Metabolism ◽

Pediatric Endocrinology ◽

Simple Method ◽

Endocrinology Clinic

Childhood obesity is a problem of growing importance globally. It is associated with significant health problems. Knowing how to treat it effectively would improve the quality of life of these children. The aim of this chapter is to study how basal metabolism influences the somatometric evolution of the child and adolescent population with obesity in a pediatric endocrinology clinic. Study childhood obesity in a tertiary hospital by means of a multichannel impedanceometry study. All the patients had a basal metabolism lower than the calculated theoretical ideal. In overall terms, weight reduction is not achieved in this pediatric population. However, it is observed a decrease in fat content in the medium term (1-3 years). Bioelectrical impedanceometry measurement is a simple method in clinical practice to evaluate the energy consumption and the body composition. Knowing the body composition of these children would help to intervene more effectively to help control obesity and its health consequences.

Download Full-text

Anxiety and Type 1 Diabetes Management: Guardian and Child Report in a Pediatric Endocrinology Clinic

Psychosomatics ◽

10.1016/j.psym.2019.11.006 ◽

2020 ◽

Vol 61 (3) ◽

pp. 231-237

Author(s):

Susan Samuels ◽

Emily V. Menand ◽

Elizabeth A. Mauer ◽

Sasha Hernandez ◽

Darya Terekhova ◽

...

Keyword(s):

Type 1 Diabetes ◽

Diabetes Management ◽

Pediatric Endocrinology ◽

Child Report ◽

Endocrinology Clinic

Download Full-text

Delayed Bone Age Might Accelerate the Response to Human Growth Hormone Treatment in Small for Gestational Age Children with Short Stature

International Journal of Endocrinology ◽

10.1155/2019/8454303 ◽

2019 ◽

Vol 2019 ◽

pp. 1-6

Author(s):

Jung-Eun Moon ◽

Cheol Woo Ko

Keyword(s):

Growth Hormone ◽

Short Stature ◽

Gestational Age ◽

Small For Gestational Age ◽

Human Growth ◽

Bone Age ◽

Pediatric Endocrinology ◽

Gh Therapy ◽

Gh Treatment ◽

The Impact

Purpose. Growth hormone (GH) treatment is recommended to improve growth and psychosocial problems in short stature children born small for gestational age (SGA). Although GH therapy in these patients has been extensively studied, the impact of therapy according to delays in bone age (BA) is not known well. Objective. To investigate the effects of GH therapy in SGA patients with short stature according to BA delay. Methods. We retrospectively analyzed changes in height SD score (SDS) and BA/chronological age (CA) after 6 and 12 months of GH therapy in patients grouped according to BA delay. We studied 27 SGA children with short stature in the pediatric endocrinology clinic of Kyungpook National University Children’s Hospital. Results. Of the 27 patients, 9 had <2 years of BA delay, while 18 had >2 years of delay. There were no significant differences between the two groups in terms of gestational age and weight at birth, height SDS, IGF-1 SDS, and growth hormone dosage at the beginning of therapy. However, height SDS increased significantly in the group with >2 years of BA delay after 6 months of GH therapy (−2.50 ± 0.61 vs −1.87 ± 0.82; p=0.037) and 12 months (−2.27 ± 0.70 vs −1.63 ± 0.65; p=0.002). When height SDS was compared between with and without GHD, there were no significant differences. Conclusions. Delayed BA (>2 years) may impact the response to GH treatment in SGA children with short stature.

Download Full-text

Disorders of sex development among Sudanese children: 5-year experience of a pediatric endocrinology clinic

Journal of Pediatric Endocrinology and Metabolism ◽

10.1515/jpem-2011-0467 ◽

2012 ◽

Vol 25 (11-12) ◽

Cited By ~ 8

Author(s):

Mohamed Ahmed Abdullah ◽

Umsalama Saeed ◽

Asjjad Abass ◽

Karib Lubna ◽

Arabi Weam ◽

...

Keyword(s):

Disorders Of Sex Development ◽

Pediatric Endocrinology ◽

Sex Development ◽

Endocrinology Clinic

Download Full-text

SAT-105 The Natural History of Pituitary Cysts in Patients with Growth Hormone Deficiency and Idiopathic Short Stature

Journal of the Endocrine Society ◽

10.1210/jendso/bvaa046.228 ◽

2020 ◽

Vol 4 (Supplement_1) ◽

Author(s):

Zeyad El-Naghy ◽

Nicholas Andrew Krasnow ◽

James Haigney ◽

Tara Patale ◽

Liam McGuirk ◽

...

Keyword(s):

Growth Hormone ◽

Short Stature ◽

Idiopathic Short Stature ◽

Hormone Deficiency ◽

Pediatric Endocrinology ◽

Post Contrast ◽

Pituitary Cyst ◽

Pituitary Cysts ◽

Over Time

Abstract Background: The sequential follow-up of simple fluid-filled pituitary cysts (PC) has not been fully elucidated. In this study, we further report our follow up of PCs in a cohort of pediatric patients (PTs). Objective: To further analyze the sequential cyst volume (CV) change in short children. Patients and Methods: A pediatric endocrinology and neuroradiology center was queried for the presence of PCs. PTs who underwent multiple high resolution post-contrast MRIs (1mm slices) were subjects of this study. PTs with additional MRI abnormalities were excluded. Pituitary volumes (PV) and CVs were measured using the ellipsoid formula (LxWxH/2). The percentage of the gland occupied by the cyst (POGO) was measured and calculated. A cyst with a POGO ≤15% was defined as a small pituitary cyst (SPC), and a POGO >15% was defined as a large pituitary cyst (LPC). 34 PTs met inclusion criteria, all of whom were diagnosed with short stature (23 growth hormone deficient (GHD) PTs and 11 idiopathic short stature (ISS) PTs). All PTs were receiving GH during data collection. Results: The mean (MN) and median (MD) ages for these subjects were 10.7 yrs ±3.5 and 11.1 yrs, respectively (RSP). Of the 34 PTs, 24 PTs’ (71%) initial MRI demonstrated a SPC and 10 PTs’ (29%) initial MRI demonstrated a LPC. The MN and MD times between first and second MRIs were 1.23 yrs and 0.83 yrs RSP, with a range (RG) of 0.14 to 4.08 yrs. The MN and MD ΔCV for all PTs was 23.33% ±179.17% and -25.94% RSP, with a RG of -100.00% to 763.94%. The MN and MD ΔPOGO by the cyst for all PTs was 48.59% ±313.26% and -36.84% RSP, with a RG of -100.00% to 1734.79%. The MN and MD ΔCV for PTs with a SPC was 10.68% ±2.65% and 11.09% RSP, with a RG of -100.00% to 763.94%. The MN and MD ΔPOGO by the cyst for PTs with a SPC was 78.33% ±369.96% and -31.34% RSP, with a RG of -100.00% to 1734.79%. The MN and MD ΔCV for PTs with a LPC was -24.60% ±51.89% and -26.57% RSP, with a RG of -88.57% to 91.38%. The MN and MD ΔPOGO by the cyst for PTs with a LPC was -22.79% ±44.90% and -40.46% RSP, with a RG of -80.95% to 47.11%. Statistical analysis showed no significant %ΔCV or %ΔPOGO when comparing male vs. female, SPC vs. LPC, GHD vs. ISS, or pre-pubertal vs. pubertal PTs. Analysis of ΔPOGO of the 24 SPC PTs demonstrated that 4 (17%) of them developed into LPCs. Analysis of the 10 LPC PTs showed that 6 (60%) of them shrunk into SPCs, one of which re-enlarged into a LPC, and another of which fluctuated between LPC and SPC over a period of 7.34 yrs and 9 sequential MRIs. None of the PTs experienced significant sequelae related to their PCs. Conclusion: CV can change greatly over time, however few sequelae should be expected. LPCs tend to demonstrate major changes in size and should be tracked for CV change. A minority of SPCs will develop into LPCs. Prediction of change in CV over time requires more sequential data. Change in CV did not appear to be influenced by GH therapy.

Download Full-text